SAN RAFAEL, Calif., Nov. 15, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the French National Agency for Medicines and Health Products Safety (ANSM) has granted an Autorisation Temporaire d'Utilisation de cohorte (ATU cohort), or Temporary Authorization for Use, for patient sales of Vimizim for the treatment of Morquio A Syndrome. An ATU is the regulatory mechanism used by the ANSM to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows patients with Morquio A Syndrome in France to receive treatment with Vimizim before marketing authorization for the product is granted in the European Union. Government allocations to hospitals allow payment for Vimizim for patients included in the ATU program. The company expects to book revenue on named-patient basis sales and will continue to assist patients in France wherever possible prior to full market product approval in the European Union.
BioMarin Announces French ATU Granted For Vimizim(TM) For The Treatment Of Morquio A Syndrome
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts